EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure | chr17:44299690-44304008:- | ENST00000586388.1 | ENSG00000267750.4 | RUNDC3A-AS1 | ncRNA_exonic | (AAAC)n,LTR50,AluSx1,AluSp,ERVL-B4-int,AluJb,AluJr,AluSx,LTR16C,L1MB3,AluSz,FLAM_A | chr17:44299690-44304008:-.alignment |
chr17:44299690-44304008:- | ENST00000588097.4 | ENSG00000267750.4 | RUNDC3A-AS1 | ncRNA_exonic | (AAAC)n,LTR50,AluSx1,AluSp,ERVL-B4-int,AluJb,AluJr,AluSx,LTR16C,L1MB3,AluSz,FLAM_A | chr17:44299690-44304008:-.alignment |
ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
chr17:44299690-44304008:- | ACC | EER | B_cells_memory | 1.1523e-02 | -0.4968 |  |
ENSG00000267750.4,RUNDC3A-AS1 | ACC | EAG | B_cells_memory | 1.1523e-02 | -0.4968 |  |
chr17:44299690-44304008:- | KICH | EER | B_cells_memory | 2.8577e-03 | 0.4132 |  |
ENSG00000267750.4,RUNDC3A-AS1 | KICH | EAG | B_cells_memory | 2.8577e-03 | 0.4132 |  |
chr17:44299690-44304008:- | LGG | EER | Mast_cells_resting | 9.9862e-03 | 0.3104 |  |
ENSG00000267750.4,RUNDC3A-AS1 | LGG | EAG | Mast_cells_resting | 9.9862e-03 | 0.3104 |  |
ENSG00000267750.4,RUNDC3A-AS1 | LUAD | EAG | T_cells_CD4_memory_resting | 1.1377e-02 | -0.5178 |  |
ENSG00000267750.4,RUNDC3A-AS1 | LUSC | EAG | Macrophages_M2 | 1.3692e-02 | -0.4960 |  |
chr17:44299690-44304008:- | PCPG | EER | T_cells_follicular_helper | 3.1444e-02 | 0.2504 |  |
ENSG00000267750.4,RUNDC3A-AS1 | PCPG | EAG | T_cells_follicular_helper | 3.1444e-02 | 0.2504 |  |
chr17:44299690-44304008:- | PRAD | EER | Macrophages_M2 | 1.8231e-02 | -0.3506 |  |
ENSG00000267750.4,RUNDC3A-AS1 | PRAD | EAG | Macrophages_M2 | 1.8231e-02 | -0.3506 |  |
chr17:44299690-44304008:- | THCA | EER | Dendritic_cells_resting | 4.1641e-05 | 0.2075 |  |
ENSG00000267750.4,RUNDC3A-AS1 | THCA | EAG | Dendritic_cells_resting | 4.1641e-05 | 0.2075 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
chr17:44299690-44304008:- | ACC | GSVA_HALLMARK_IL2_STAT5_SIGNALING | EER | 5.6986e-03 | 0.5365 |  |
ENSG00000267750.4,RUNDC3A-AS1 | ACC | GSVA_HALLMARK_IL2_STAT5_SIGNALING | EAG | 5.6986e-03 | 0.5365 |  |
chr17:44299690-44304008:- | BRCA | GSVA_HALLMARK_HYPOXIA | EER | 4.4303e-03 | 0.3006 |  |
ENSG00000267750.4,RUNDC3A-AS1 | BRCA | GSVA_HALLMARK_HYPOXIA | EAG | 4.4303e-03 | 0.3006 |  |
chr17:44299690-44304008:- | ESCA | GSVA_HALLMARK_TGF_BETA_SIGNALING | EER | 1.0696e-02 | 0.5446 |  |
ENSG00000267750.4,RUNDC3A-AS1 | ESCA | GSVA_HALLMARK_TGF_BETA_SIGNALING | EAG | 1.0696e-02 | 0.5446 |  |
ENSG00000267750.4,RUNDC3A-AS1 | LUSC | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 3.5131e-02 | 0.4318 |  |
chr17:44299690-44304008:- | OV | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 3.5636e-03 | 0.5411 |  |
ENSG00000267750.4,RUNDC3A-AS1 | OV | GSVA_HALLMARK_UV_RESPONSE_UP | EAG | 3.5636e-03 | 0.5411 |  |
ENSG00000267750.4,RUNDC3A-AS1 | PCPG | GSVA_HALLMARK_MYC_TARGETS_V1 | EAG | 5.5033e-03 | 0.3196 |  |
chr17:44299690-44304008:- | PCPG | GSVA_HALLMARK_MYC_TARGETS_V1 | EER | 5.5033e-03 | 0.3196 |  |
ENSG00000267750.4,RUNDC3A-AS1 | PRAD | GSVA_HALLMARK_MYC_TARGETS_V1 | EAG | 4.4542e-03 | -0.4162 |  |
chr17:44299690-44304008:- | PRAD | GSVA_HALLMARK_MYC_TARGETS_V1 | EER | 4.4542e-03 | -0.4162 |  |
chr17:44299690-44304008:- | THCA | GSVA_HALLMARK_COAGULATION | EER | 1.8970e-05 | 0.2164 |  |
ENSG00000267750.4,RUNDC3A-AS1 | THCA | GSVA_HALLMARK_COAGULATION | EAG | 1.8970e-05 | 0.2164 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
chr17:44299690-44304008:- | ACC | Bexarotene | EER | 4.0968e-02 | -0.4115 |  |
ENSG00000267750.4,RUNDC3A-AS1 | ACC | Bexarotene | EAG | 4.0968e-02 | -0.4115 |  |
chr17:44299690-44304008:- | BRCA | CCT018159 | EER | 8.9104e-03 | -0.2773 |  |
ENSG00000267750.4,RUNDC3A-AS1 | BRCA | CCT018159 | EAG | 8.9104e-03 | -0.2773 |  |
chr17:44299690-44304008:- | ESCA | MG.132 | EER | 2.0331e-02 | 0.5022 |  |
ENSG00000267750.4,RUNDC3A-AS1 | ESCA | MG.132 | EAG | 2.0331e-02 | 0.5022 |  |
ENSG00000267750.4,RUNDC3A-AS1 | KICH | AS601245 | EAG | 1.5001e-03 | -0.4372 |  |
chr17:44299690-44304008:- | KICH | AS601245 | EER | 1.5001e-03 | -0.4372 |  |
ENSG00000267750.4,RUNDC3A-AS1 | LGG | GDC.0449 | EAG | 4.1974e-02 | 0.2474 |  |
chr17:44299690-44304008:- | LGG | GDC.0449 | EER | 4.1974e-02 | 0.2474 |  |
ENSG00000267750.4,RUNDC3A-AS1 | LUAD | BAY.61.3606 | EAG | 8.4266e-03 | 0.5357 |  |
ENSG00000267750.4,RUNDC3A-AS1 | LUSC | GW.441756 | EAG | 5.7349e-03 | 0.5464 |  |
chr17:44299690-44304008:- | OV | Lenalidomide | EER | 4.1796e-03 | 0.5427 |  |
ENSG00000267750.4,RUNDC3A-AS1 | OV | Lenalidomide | EAG | 4.1796e-03 | 0.5427 |  |
ENSG00000267750.4,RUNDC3A-AS1 | PCPG | CCT007093 | EAG | 1.9010e-02 | 0.2721 |  |
chr17:44299690-44304008:- | PCPG | CCT007093 | EER | 1.9010e-02 | 0.2721 |  |
ENSG00000267750.4,RUNDC3A-AS1 | PRAD | JNK.9L | EAG | 9.4883e-03 | -0.3826 |  |
chr17:44299690-44304008:- | PRAD | JNK.9L | EER | 9.4883e-03 | -0.3826 |  |
chr17:44299690-44304008:- | THCA | AZD.0530 | EER | 1.0815e-04 | -0.1963 |  |
ENSG00000267750.4,RUNDC3A-AS1 | THCA | AZD.0530 | EAG | 1.0815e-04 | -0.1963 |  |